Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$360.00
-1.00 (-0.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.0B · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.6%
↓Gross Margin
23.6%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.8%
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
-0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $43.16B · net income $-11.46B · FCF $1.35B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $43.16B | $43.16B | $37.87B | $36.31B | $27.83B |
| Net Income | $-11.46B | $-11.46B | $-26.32B | $13.91B | $-42.08B |
| EBITDA | $-1.79B | $-1.79B | $-18.23B | $18.80B | $-36.77B |
| EPS | -239.00 | -239.00 | -200.03 | 2763.24 | -1070.25 |
| Gross Margin | 23.6% | 23.6% | 27.2% | 26.4% | 20.4% |
| Operating Margin | 1.7% | 1.7% | -0.2% | 2.7% | -14.6% |
| Net Margin | -26.5% | -26.5% | -69.5% | 38.3% | -151.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.67 | 0.26 | 0.36 |
| Current Ratio | 1.24 | 1.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.35B | $1.35B | $-3.76B | $-3.03B | $-2.93B |
| Returns | |||||
| ROE | -10.6% | -10.6% | -31.8% | 13.3% | -50.0% |
| Valuation | |||||
| P/E | — | — | — | 0.84 | — |
| EV/EBITDA | — | — | — | 7.85 | — |
| P/B | 0.16 | 0.16 | 2.32 | 1.23 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | 14.0% | 14.0% | 4.3% | 30.5% | — |
| EPS Growth | -19.5% | -19.5% | -107.2% | 358.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-200.03 → -239.00
Residual
-66.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.